glp1 and glp2 tirzepatide Frontiers TrimRX | GLP-1 vs GIP:
Description
620 Lyu, Y
Total: 3mg used within 28 days, with 2mg remaining
The risks of microdosing are significant and multifaceted: Therapeutic inefficacy : Sub-therapeutic doses may fail to achieve meaningful improvements in glycaemic control or weight management, potentially delaying appropriate treatment and allowing disease progression
Safe, evidence-based alternatives include dietary modification following the NHS Eatwell Guide, regular moderate-intensity exercise, and NHS-commissioned Tier 2 weight management programmes
At Revolution Health, we specialize in personalized, functional medicine approaches to weight loss and metabolic health
The latter, she says, will have had praise for their weight loss
